The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > COLUMN
COLUMN
-
Current Topics of New Drug Development and Marketing in the World: 2
July 10, 2015
-
Current Topics of New Drug Development and Marketing in the World: 1
July 9, 2015
-
The Mastery of Recruitment
June 26, 2015
-
“Every Search Is Won Before It’s Ever Fought”: Sun Tzu
May 22, 2015
-
The Truth about Recruiters
April 21, 2015
-
When Interviewing, Share the Love
March 27, 2015
-
Sales Experience for Marketers Deceasing in Japan’s Pharma Industry
February 20, 2015
-
Eliminating Bias from the Interview Process
January 23, 2015
-
Loss Aversion: Why Candidates Reject Offers
December 26, 2014
-
What You Don’t Know About Communication Can Hurt You
November 28, 2014
-
3 Reasons Why KOL Management Is No Longer Enough
October 22, 2014
-
Successful People Have the Best Information
September 24, 2014
-
Is Your Body Language Louder than Your Speech?
August 25, 2014
-
Taking Pride in Small Things Makes Big Things Possible
July 25, 2014
-
It’s Moments Like These
June 27, 2014
-
How to Hire a Medical Doctor Who Is a Business Person First
May 23, 2014
-
Transforming from a Key Opinion Leader to a Key Account
April 25, 2014
-
Emerging Immunotherapy of Cancer: 2
April 11, 2014
-
Emerging Immunotherapy of Cancer: 1
April 10, 2014
-
Sun Tzu and the Art of Interviewing
March 18, 2014
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…